Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP4345 for Cognitive Impairment in Schizophrenia
NCT03557931Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ASP4345 in schizophrenia, sponsored by Astellas Pharma. Started Jul 2018; status: completed.
02
Drugs
ASP4345
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03557931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03557931.